| 2021 | GLOBAL MARKETS LIVE : Airbus, BP, Merck, Pfizer, Meta... | |
| 2021 | Bristol Myers Squibb Gets FDA Acceptance of sBLA for Reblozyl | DJ |
| 2021 | ACCELERON PHARMA INC.(NASDAQGM : XLRN) dropped from NASDAQ Biotechnology Index | CI |
| 2021 | ACCELERON PHARMA : Completion of Acquisition or Disposition of Assets - Form 8-K | PU |
| 2021 | Merck Completes Acceleron Pharma Acquisition | MT |
| 2021 | Merck Completes Tender Offer to Acquire Acceleron Pharma Inc. | AQ |
| 2021 | Merck Completes Cash Tender Offer to Purchase Acceleron Pharma at $180/Share | MT |
| 2021 | ACCELERON PHARMA INC.(NASDAQGM : XLRN) dropped from S&P Biotechnology Select Industry Inde.. | CI |
| 2021 | ACCELERON PHARMA INC.(NASDAQGM : XLRN) dropped from S&P TMI Index | CI |
| 2021 | ACCELERON PHARMA INC.(NASDAQGM : XLRN) dropped from S&P Global BMI Index | CI |
| 2021 | ACCELERON PHARMA INC.(NASDAQGM : XLRN) dropped from NASDAQ Composite Index | CI |
| 2021 | Merck Completes Tender Offer to Acquire Acceleron Pharma Inc | CI |
| 2021 | Merck Sharp & Dohme Corp. completed the acquisition of Acceleron Pharma Inc. from Avoro.. | CI |
| 2021 | Avoro Capital Urges Acceleron Shareholders Not to Tender Into Merck's 'Inadequate' Offe.. | MT |
| 2021 | Avoro Capital Urges Acceleron Shareholders Not to Tender Into Merck's Inadequate Offer | BU |
| 2021 | Merck Extends Tender Offer for Acceleron Pharma | MT |
| 2021 | Avoro Capital Releases Presentation Detailing Why Acceleron Shareholders Should Not Ten.. | BU |
| 2021 | Acceleron Reports Third Quarter 2021 Financial Results - Form 8-K | PU |
| 2021 | ACCELERON : Q3 Earnings Snapshot | AQ |
| 2021 | Acceleron Pharma Inc. Reports Earnings Results for the Third Quarter and Nine Months En.. | CI |
| 2021 | Acceleron Pharma Inc. Reports Earnings Results for the Third Quarter and Nine Months En.. | CI |
| 2021 | Earnings Flash (XLRN) ACCELERON PHARMA Reports Q3 Loss $-0.95 | MT |
| 2021 | Acceleron Reports Third Quarter 2021 Financial Results | BU |
| 2021 | SHAREHOLDER ALERT : WeissLaw LLP Reminds DWSN, PAE, XLRN, and FLXN Shareholders About Its .. | PR |
| 2021 | Merck Announces Withdrawal and Refiling under the Hart-Scott-Rodino Act and Extension o.. | AQ |
| 2021 | Merck Extends FTC Review Period for Acceleron Buyout | MT |
| 2021 | Avoro Capital Issues Open Letter to Fellow Acceleron Pharma Shareholders | BU |
| 2021 | Acceleron Pharma Sees Q3 Reblozyl Royalty Revenue at $32 Million Based on Net Sales of .. | MT |
| 2021 | Acceleron Announces Third Quarter 2021 REBLOZYL® Net Sales | BU |
| 2021 | Acceleron Pharma Inc. Provides Revenue Guidance for the Third Quarter Ended September 3.. | CI |
| 2021 | MERCK : Bristol-Myers To Shed Acceleron Stake Ahead Of Merck & Co.'s $11.5 Billion Acquisi.. | MT |
| 2021 | ACCELERON PHARMA ALERT : Investors Should Contact Bragar Eagel & Squire, P.C. Over Tender .. | BU |
| 2021 | MERCK : Acceleron Pharma Shareholder Says Merck & Co.'s Offer Significantly Undervalues Co.. | MT |
| 2021 | SHAREHOLDER ALERT : Monteverde & Associates PC Announces an Investigation of Acceleron Pha.. | PR |
| 2021 | ACCELERON PHARMA : Holocene Advisors says Merck's offer undervalues Acceleron | RE |
| 2021 | ACCELERON PHARMA : Holocene Advisors says Merck's offer undervalues Acceleron | RE |
| 2021 | MERCK : Launches Tender Offer to Buy Acceleron Pharma at $180 Per Share | MT |
| 2021 | ACCELERON PHARMA : Jefferies Starts Acceleron Pharma at Hold With $180 Price Target | MT |
| 2021 | ACCELERON PHARMA : Raymond James Downgrades Acceleron Pharma to Market Perform From Strong.. | MT |
| 2021 | ACCELERON INVESTOR ALERT BY THE FORM : Kahn Swick & Foti, LLC Investigates Adequacy of Pri.. | BU |
| 2021 | SHAREHOLDER INVESTIGATION : Halper Sadeh LLP Investigates XLRN, ADTN, DSPG, KDMN; Sharehol.. | PR |
| 2021 | ACCELERON PHARMA : Oppenheimer Suspends Rating for Acceleron Pharma, $160 Price Target on .. | MT |
| 2021 | ACCELERON PHARMA : Morgan Stanley Downgrades Acceleron Pharma to Equalweight from Overweig.. | MT |
| 2021 | ACCELERON PHARMA : Barclays Downgrades Acceleron Pharma to Equal-Weight Rating From Overwe.. | MT |
| 2021 | WALL STREET STOCK EXCHANGE : Autumn cold snap | |
| 2021 | ACCELERON PHARMA : Cowen Downgrades Acceleron Pharma to Market Perform from Outperform, Bo.. | MT |
| 2021 | ANALYST RECOMMENDATIONS : Acceleron Pharma, General Mills, Southwest Airlines, Home Depot,.. | |
| 2021 | NORTH AMERICAN MORNING BRIEFING : Fears Heighten -2- | DJ |
| 2021 | MERCK : to Buy Rare Disease Specialist Acceleron for $11.5 Billion | MT |
| 2021 | Merck to buy Acceleron for about $11.5 billion in rare disease drug push | RE |
| 2021 | Health Care Down, But Not By Much, As Deal Activity Cushions Losses - Health Care Round.. | DJ |
| 2021 | Avoro Capital Discloses its Views on Proposed Acquisition of Acceleron Pharma to Merck .. | CI |
| 2021 | ACCELERON PHARMA : Avoro Capital Believes Proposed Acquisition of Acceleron Pharma by Merc.. | BU |
| 2021 | Health Care Stocks Closing Slightly Lower After Early Gains | MT |
| 2021 | ACCELERON MERGER INVESTIGATION : Halper Sadeh LLP Announces Investigation Into Whether the.. | BU |
| 2021 | Health Care Stocks Unable to Sustain Early Rise | MT |
| 2021 | ACCELERON PHARMA : HC Wainwright Downgrades Acceleron Pharma to Neutral Rating From Buy, A.. | MT |
| 2021 | ACCELERON PHARMA : RBC Capital Again Raises Price Target for Acceleron Pharma to $180 From.. | MT |
| 2021 | ACCELERON PHARMA : SVB Leerink Adjusts Acceleron Pharma PT to $180 from $148, Keeps Market.. | MT |
| 2021 | ACCELERON PHARMA : Piper Sandler Downgrades Acceleron Pharma to Neutral from Overweight, A.. | MT |
| 2021 | SHAREHOLDER ALERT : Ademi LLP investigates whether Acceleron Pharma Inc. has obtained a Fa.. | PR |
| 2021 | WALL STREET STOCK EXCHANGE : Markets take a breather after the purge | |
| 2021 | MERCK : to Buy Acceleron for $11.5 Billion, or $180 Per Share in Cash, to Expand Cardiovas.. | MT |
| 2021 | ACCELERON PHARMA : Merck spends $11.5B for Acceleron, possible blockbuster drug | AQ |
| 2021 | Health Care Stocks Gain Premarket Thursday | MT |
| 2021 | ACCELERON PHARMA : REBLOZYL® (luspatercept-aamt) is a First-In-Class Erythroid Maturation .. | PU |
| 2021 | Merck to Buy Acceleron Pharma for $11.5 Billion | DJ |
| 2021 | MERCK : to Acquire Acceleron Pharma in $11.5 Billion Deal | MT |
| 2021 | Merck Sharp & Dohme Corp. ("MSD") entered into a definitive agreement to acquire Accele.. | CI |
| 2021 | GLOBAL MARKETS LIVE : Airbus, Merck, Geely, Toyota, Activision Blizzard... | |
| 2021 | WALL STREET STOCK EXCHANGE : Is inflation still transitionary? | |
| 2021 | NORTH AMERICAN MORNING BRIEFING : Stock Futures Slip as Bond Yields Hit Three-Month High | DJ |
| 2021 | MERCK : Reportedly in Advanced Talks to Buy Acceleron Pharma | MT |
| 2021 | MERCK : Said to Buy Acceleron Pharma in Rare Diseases Boost | MT |
| 2021 | ACCELERON PHARMA : Merck in advanced talks to buy Acceleron Pharma - WSJ | RE |
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (Nederland)
Nederlands (België)
